Bayer HealthCare announced that initial results from a Phase 2 study of Portola Pharmaceuticals’ andexanet alfa, an investigational Factor Xa inhibitor antidote, in healthy volunteers who were administered Bayer’s anticoagulant Xarelto have been accepted for presentation at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition.
GlaxoSmithKline today announced the phase 3 trial evaluating the efficacy of its investigational Lp-PLA2 inhibitor darapladib in adults with chronic coronary heart disease (CHD) did not meet its primary endpoint. What does this mean for the drug's future? Find out...
ImmunoGen Inc. announced that Novartis has licensed the exclusive right to use the company's antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target.
Israel's Teva Pharmaceuticals Industries Ltd. says it has reached an agreement with the country's tax authority to pay roughly $718 million to settle a series of claims against the drug maker.
Researchers successfully eliminated the native infection preferences of a Sindbis virus engineered to target and kill cancer cells, a milestone in the manipulation of this promising viral vector.
Shares of Zalicus tumbled to an all-time low today after the company said it is ending development of its most advanced experimental drug. The pain drug developer said drug candidate Z160 failed in two mid-stage clinical trials.
Shares of Arena Pharmaceuticals continued to rise today after the company expanded a marketing partnership with Eisai Co. of Japan on its weight-loss drub Belviq.
Shares of Alnylam Pharmaceuticals Inc. rose faster than the broader market today after the drug developer said its potential treatment for a rare, fatal disease received a fast-track designation from U.S. regulators.
The Food and Drug Administration is seeking a rule change to allow generic drugmakers to quickly update their warning labels with new safety information for doctors and patients.
Pharmaceutical company Novartis says it is selling part of its diagnostics business to the Spanish health care company Grifols for $1.68 billion. The deal requires customary regulatory approvals but is expected to be completed in the first half of 2014.
Breast cancers that initially respond to hormone therapies such as tamoxifen eventually become resistant to treatment, and a new study finds this may be because of a mutation in the receptor present in the cancer cell to which tamoxifen binds.
Drug maker Shire says it is buying the rare disease biopharmaceutical company ViroPharma in a deal worth $4.2 billion. Shire PLC will pay $50 a share, a 27 percent premium on last week's closing price.
A team of scientists has identified a new way to intervene in the molecular and cellular cascade that causes fibrosis. Could this lead to a novel therapeutic approach to treat fibrotic diseases such as idiopathic pulmonary fibrosis and liver fibrosis? Find out...
AstraZeneca today announced plans to invest £120 million ($190 million) in a new facility at its global manufacturing site in Macclesfield, UK, to continue production of Zoladex, an injectable treatment for patients with prostate cancer. How many jobs will this investment secure? Find out...
Researchers have discovered that the formation of blood clots follows a different molecular route in African Americans versus European Americans, providing a new understanding of the effects of race on heart disease. Could the finding provide more individualized treatment of heart disease and other blood-clot-related illnesses? Find out...